Skip to content

Advertisement

  • Research article
  • Open Access

Prevalence and associated factors of resting electrocardiogram abnormalities among systemic lupus erythematosus patients without cardiovascular disease

  • 1,
  • 2,
  • 1, 3,
  • 1,
  • 1,
  • 1, 3 and
  • 1Email author
Arthritis Research & Therapy201719:31

https://doi.org/10.1186/s13075-017-1240-1

©  The Author(s). 2017

  • Received: 21 September 2016
  • Accepted: 20 January 2017
  • Published:

Abstract

Background

Electrocardiogram (ECG) cardiovascular disease (CVD) abnormalities (ECG-CVD) are predictive of subsequent CVD events in the general population. Systemic lupus erythematosus (SLE) patients are vulnerable to CVD. We aimed to determine the prevalence of ECG-CVD in SLE patients and to examine the risk factors associated with ECG-CVD.

Methods

A 12-lead resting supine ECG was performed on consecutive adult patients attending the clinic. One cardiologist interpreted the ECGs. ECG-CVD were defined as the presence of one or more of the following 4 elements (ECG-4): ST-segment and/or T-wave abnormalities, left ventricular hypertrophy (LVH), left axis deviation (LAD), left bundle branch block (LBBB) and right bundle branch block (RBBB). ECG-5 included the same elements as ECG-4 and the Q-wave. Repeated measurement data were created and the associations between ECG-4/ECG-5 and demographics were evaluated with univariate and multivariate Cox regression models.

Results

Of 487 SLE patients, 104 (21.4%) and 118 (24.2%) patients had one or more of the ECG-4 and ECG-5 elements, respectively. A higher prevalence of ECG-CVD was found in patients with a longer SLE disease duration, and the burden of ECG-CVD elements increased with age. Increased age, active SLE disease, and damage were associated with ECG4 and ECG-5, while treatment of hyperlipidemia was protective.

Conclusion

A high prevalence of ECG-4 (21.4%) and ECG-5 (24.2%) was found in this SLE cohort. Controlling SLE disease activity is important since it was associated with ECG-4 and ECG-5. Early identification of ECG-4 and ECG-5 in SLE patients might allow for better stratification and risk management.

Keywords

  • Cardiovascular disease
  • Systemic lupus erythematosus
  • Electrocardiogram

Background

Substantial progress has been made in the awareness and prevention of coronary artery disease (CAD) in patients with systemic lupus erythematosus (SLE) since the first published reports in long-term observational cohort studies of clinical CAD in an estimated 6–10% of SLE patients [1, 2]. The prevalence of myocardial infarction (MI)/angina and sudden death in the Toronto SLE clinic was approximately 10% in 1995 [3], and a similar prevalence of CAD has been reported in other SLE cohorts [4, 5]. SLE is now recognized as an independent risk factor for cardiovascular disease (CVD) [6] and, as such, was incorporated into the recently revised American Heart Association guidelines for the prevention of CVD in women [7]. Abnormalities detected on resting electrocardiogram (ECG) in healthy adults are associated with an increased risk for subsequent CVD events [8]. In a systematic review, Chou et al. [8] found that resting ECG abnormalities (ECG-CVD 4-elements), in particular ST-segment and/or T-wave abnormalities, left ventricular hypertrophy (LVH), left axis deviation (LAD), left bundle branch block (LBBB) and right bundle branch block (RBBB), were associated with subsequent CVD events (e.g., sudden coronary heart disease death, nonfatal myocardial infarction, and congestive heart failure). In their systematic review, Chou et al. reported other resting ECG abnormalities (e.g., prolonged QT interval, Q waves, arrhythmia, and others) but these ECG findings were evaluated by too few studies or were too variably defined to have clear conclusions about their usefulness as predictors of subsequent CVD events [8]. The objective of this study was to determine the prevalence of ECG-CVD (4-elements (ECG-4) as per Chou et al., and 5-elements (ECG-5) as per Chou et al. or Q wave) in a cohort of SLE patients, and to examine the factors associated with ECG-4 and ECG-5.

Methods

Setting

A standard digitally recorded 12-lead resting supine ECG was performed on consecutive adult SLE patients ≥18 years, with 4 or more of the American College of Rheumatology (ACR) criteria or 3 ACR criteria plus a typical histological lesion of SLE on renal or skin biopsy [9] attending the University of Toronto SLE Clinic from October 2011 to November 2015. All patients were evaluated according to the standard clinic protocol which includes demographics, assessment of disease activity (SLE Disease Activity Index 2000 (SLEDAI-2 K)) [10] and damage (SLICC/American College of Rheumatology Damage Index (SDI)) [11], current and past glucocorticoid, antimalarial, antihypertensive, and immunosuppressant medication use, and laboratory tests at each visit. Patients were followed prospectively every 2 to 6 months. The following data were collected on all patients as part of the regular databank protocol and were made available for this study. Patients were considered to have a positive smoking status if they were documented as a current smoker at any point in the 5 years preceding the date of ECG. History of cardiovascular events (MI, angina, angioplasty, congestive heart failure and pacemaker), diabetes mellitus (DM) 3 years before ECG, hyperlipidemia on statins ever prior to ECG, and hypertension within 5 years from ECG (>140 mmHg systolic or >90 diastolic mmHg, or using medication for hypertension) were extracted. Patients were considered positive for antiphospholipid antibodies (aPLA) if they had ever been positive for aPLA, including total anticardiolipin antibodies and individual anticardiolipin antibodies (aCL IgG/aCL IgM) (Phadia Varelisa kits, Somagen for anticardiolipin antibodies screen and IgG and IgM assays) measured yearly by enzyme-linked immunosorbent assay (ELISA) [12]. The clotting assays for SLE anticoagulant included the dilute Russell viper venom time and the platelet neutralization procedure. SLE anticoagulant (LA) was considered present if patients tested positive on two or more occasions since joining the SLE cohort. Other laboratory variables were evaluated: ANA, anti-ds DNA, anti-Ro, anti-La, anti-Smith, anti-RNP, anti-Jo1 antibodies, ANCA, and Coombs tests (ever-positive 5 years prior to ECG).

The ECGs had all identifying data removed and so were read “blind”. The coded 12-lead ECGs were evaluated and interpreted by one senior cardiologist (PH) using the Minnesota code classification system, which is a widely used method of categorizing ECG abnormalities [13].

All patients provided informed consent for the collection, storage, and use of clinical and laboratory data following procedures in accordance with the Declaration of Helsinki and approved by the University Health Network Research Ethics Board, Toronto, Ontario, Canada.

Patient selection

Consecutive SLE patients seen at the SLE clinic from October 2011 to November 2015 were recruited to this study. Patients were excluded if they had had a CVD event (MI, angina, congestive heart failure (CHF), angioplasty and pacemaker) prior to ECG.

Study design

SLE patients were grouped into those with normal ECG and those with ECG-CVD. ECG-CVD patients were further grouped into two: ECG-4 (with one or more of the following abnormalities—LBBB/RBBB, LAD/left anterior fascicular block (LAFB), LVH, and ST-segment and/or T-wave abnormalities); and ECG-5 (any of the above or pathological Q wave) (Fig. 1). Our study focuses on patients with ECG-4 and ECG-5 compared to patients with a normal ECG. Descriptive analyses of patient demographics, disease activity, damage, and antibody abnormalities were studied in the following groups: patients with normal ECG, patients with ECG-4, and patients with ECG-5. The clinical/laboratory data available at the time of ECG were used to study the association with ECG-CVD. The adjusted mean SLEDAI-2 K (AMS) was calculated using SLEDAI-2 K 2 years prior to the ECG visit [14].
Fig. 1
Fig. 1

Study design and grouping of patients: normal electrocardiogram (ECG), non-ECG-cardiovascular disease (ECG-CVD), ECG-4, and ECG-5. Non-ECG-CVD defined as the presence of any of the following ECG abnormalities: right axis deviation, arrhythmia, sinus tachycardia, sinus bradycardia, atrioventricular blocks, atrial ectopic rhythm, and atrial enlargement

Statistical analyses

Simple statistics at baseline (at the first visit to the clinic) were described by mean and percentages for continuous and categorical variables. The differences between the group of patients with normal ECG and the group of patients with ECG-CVD (ECG-4 and ECG-5) were compared by t test and chi-square test.

A counting process data structure was created for the outcome of both ECG-4 and ECG-5. Patient sex, ethnicity, time from first visit to the clinic to the time of ECG, hypertension, hyperlipidemia on statin therapy, laboratory test (antibodies), smoking ever before ECG, disease activity, and diabetes 3 years before ECG test were extracted as time-fixed variables. Other variables such as organ damage and treatment were extracted as time-variant variables.

Univariate Cox regression was performed to test each risk factor, comparing normal ECG and ECG-4 and ECG-5. The variables with p value less than 0.2 were entered into the multivariate regression. The traditional risk factors for CAD including hypertension and smoking were forced into the model.

Cox regression proportionalities were checked by the Schoenfeld residuals, and continuous variables were tested for their linearity using Martingale residuals. The time-dependent multivariate Cox regression model was built using a step-down covariate-selection approach; Akaike information criterion (AIC) adjusting the number of covariates in the model was adopted as the method assessing the goodness of fit. Both hypertension and smoking were forcedly added to the multivariable regression but did not show an association with ECG-4 and ECG-5. The analysis was conducted using SAS (9.3) and p values <0.05 were considered statistically significant.

Results

ECG

Among the 558 adult SLE patients who had an ECG, 44% were inception (patients who joined the SLE clinic within 1 year from the diagnosis of SLE). Seventy-one patients were excluded as they had CAD before the ECG test. A total of 487 ECGs were evaluated of which 314 patients (64.4%) had a normal ECG. The prevalence of ECG-4 was 21.4% (104/487 patients) and the prevalence of ECG-5 was 24.2% (118/487 patients). The most common element of ECG-4 was ST-segment abnormalities and/or T-wave abnormalities (73/104; 70%), followed by LVH in 32%, LAD or LAFB in 20%, and LBBB or RBBB in 11%. In ECG-5, Q-wave was found in 18% (21/118) of the patients. The ECG-CVD elements were found as one ECG-CVD element in 67% (70/104) in the ECG-4, two ECG-CVD elements in 25% (26/104), and 7% (7/104) had three ECG-CVD elements. ECG-CVD was seen more often with longer disease duration (Fig. 2). Other ECG abnormalities documented in 55 patients were: right axis deviation in 9 patients, incomplete RBBB in 3 patients, atrial enlargement in 7 patients, and arrhythmia in 36 patients (sinus tachycardia in 9 patients, sinus bradycardia in 11, short PR in 8, first A-V block in 3, ectopic atrial rhythm in 3, premature atrial contraction in 3, and ventricular bigeminy in 1 (few patients had overlaping types of arrhythmia).
Fig. 2
Fig. 2

Cumulative proportions of individual ECG-5 from systemic lupus erythematosus (SLE) diagnosis up to 20 years of follow-up (e.g., 11 out of 21 (52.4%) patients had LAD/LAFB up to 20 years and the other 10 LAD/LAFB occurred after 20 years of follow-up). ECG-CVD electrocardiogram cardiovascular disease abnormalities, LAD left axis deviation, LAFB left anterior fascicular block, LBBB left bundle branch block, LVH left ventricular hypertrophy, RBBB right bundle branch block

Patient characteristics

The baseline (at first visit to the clinic) characteristics of the patients were similar in SLE patients with a normal ECG and those with ECG-CVD (Table 1). A higher prevalence of ECG-4 and ECG-5 was identified among older SLE patients. Patients with longer SLE disease duration had more prevalence of ECG-4 and ECG-5 compared to patients with a normal ECG (19.48 ± 11.03 vs. 15.23 ± 10.16, p < 0.001). Patient with longer lupus follow-up duration (13.69 ± 11.29 years) at the time of ECG had a higher prevalence of ECG-4 (p = 0.006) versus a normal ECG with a follow-up duration at the time of the ECG of 10.57 ± 9.40 years. Also, patients with longer lupus follow-up duration at the time of ECG have a higher prevalence of ECG-5. Hypertension within 5 years prior to the ECG was associated with a high prevalence of ECG-4 and ECG-5 (p = 0.015 and p = 0.006, respectively). There were no significant differences between a normal ECG and ECG-4 or ECG-5 among the other variables (SDI, SLEDAI-2 K, smoking, DM, and treatment with antimalarials or immunosuppressives) (Table 1). There was no difference in the antibodies profile between normal ECG and ECG-4 and ECG-5 (data not shown).
Table 1

Demographic and clinical characteristics of SLE patients with a normal ECG and ECG-4 and ECG-5 at the first visit

Variables

 

ECG normal

n = 314

ECG-4

n = 104

p

ECG-5

n = 118

p

Gender

 

Female

286 (91.1%)

92(88.5)

0.43

104 (88.1%)

0.357

Male

28 (8.9%)

12 (11.5%)

 

14 (11.9%)

 

Ethnicity

 

Caucasian

181 (58.2%)

59 (57.8%)

0.09

69 (59.5%)

0.146

 

Black

51 (16.4%)

26 (25.5%)

 

27 (23.3%)

 

Asian

38 (12.2%)

10 (9.8%)

 

12 (10.3%)

 

Others

41 (13.2%)

7 (6.4)

 

8 (6.9%)

 

Age at SLE diagnosis (years)

29.6 ± 11.3

30.66 ± 11.01

0.42

30.46 ± 11.86

0.50

Age at ECG (years)

44.87 ± 12.9

50.14 ± 14.1

<0.001

49.95 ± 15.01

<0.001

Disease duration at ECG (years)

15.23 ± 10.2

19.48 ± 11.03

<0.001

19.49 ± 11.44

<0.001

Follow-up duration at ECG (years)

10.57 ± 9.4

13.69 ± 11.29

0.006

13.41 ± 11.24

0.008

SLEDAI-2 K at the first visit

9.24 ± 8.3

10.2 ± 7.78

0.30

9.82 ± 7.67

0.52

SDI

0.27 ± 0.7

0.44 ± 0.92

0.07

0.44 ± 0.90

0.06

Cumulative glucocorticoid (g)

5.24 ± 16.5

9.16 ± 31.25

0.10

8.96 ± 29.85

0.10

Treated with antimalarials

147 (46.8%)

51 (49.0%)

0.69

59 (50.0%)

0.55

Treated with immunosuppressives

93 (29.6%)

33 (31.7%)

0.68

37 (31.4%)

0.73

Hypertension

153 (48.7%)

65 (62.5%)

0.015

74 (63.6%)

0.006

Hyperlipidemia on statins ever before ECG

87 (27.7%)

40 (38.5%)

0.039

44(37.3%)

0.05

DM 3 years prior to ECG

16 (5.1%)

4 (3.8%)

0.60

4 (3.4%)

0.45

Smoking ever prior to ECG

91 (29%)

30 (28.8%)

0.97

34 (28.8%)

0.91

Values are shown as mean ± SD or n (%) as appropriate

p values are from t test for means, Chi-Square test for binary variables, and Cochran-Armitage trend test for categorical variables

DM diabetes mellitus, ECG electrocardiogram, SDI SLICC/American College of Rheumatology Damage Index, SLE systemic lupus erythematosus, SLEDAI-2 K SLE Disease Activity Index 2000

Univariate analysis

Both ECG-4 and ECG-5 were significantly associated with non-Caucasian ethnicity, longer lupus disease duration, and with increasing age of the SLE patients at each visit. Patients with ECG-4 and ECG-5 had more active SLE disease activity (AMS 2 years prior to ECG visit) and more damage (SDI) compared to patients with normal ECG. Treatment, including glucocorticoids, antimalarials, and immunosuppressives, was associated with ECG-4 and ECG-5. Other classic CVD risk factors such as smoking and hypertension were not associated with ECG-4 or ECG-5 in the univariate analysis (Table 2).
Table 2

Univariate Cox regression analysis for ECG-4 and ECG-5

 

ECG-4

ECG-5

Variables

HR (95% CI)

p

HR (95% CI)

p

Non-Caucasian

1.91 (1.27–2.86)

0.002

1.63 (1.11–2.37)

0.012

Gender (male)

1.13 (0.62–2.07)

0.68

1.19 (0.68–2.09)

0.53

Age

1.03 (1.007–1.05)

0.01

1.02 (1.004–1.05)

0.02

Disease duration

1.06 (1.03–1.09)

0.0007

1.05 (1.014–1.09)

0.006

Hypertension within 5 years prior to ECG

0.88 (0.49–1.57)

0.67

0.91 (0.52–1.58)

0.73

Hyperlipidemia on statins ever before ECG

0.59 (0.30–1.13)

0.11

0.54 (0.29–1.01)

0.05

Ever smoked before ECG

0.72 (0.39–1.35)

0.31

0.75 (0.42–1.35)

0.34

Diabetes 3 years before ECG

0.75 (0.27–2.04)

0.09

0.75 (0.27–2.048)

0.57

SLEDAI-2 K

1.05 (1.012–1.013)

0.01

1.05 (1.01–1.09)

0.008

AMS 2 years prior to ECG

1.08 (1.02–1.13)

0.005

1.08 (1.03–1.13)

0.003

SDI

1.23 (1.07–1.41)

0.003

1.21 (1.06–1.39)

0.006

Cumulative glucocorticoids

1.007 (1.001–1.01)

0.02

1.007 (1.001.013)

0.02

Treated with antimalarials

2.27 (1.12–4.59)

0.02

2.11 (1.11–4.04)

0.02

Treated with immunosuppressives

2.15 (1.21–3.83)

0.009

2.06 (1.19–3.55)

0.009

Coombs

1.19 (0.81–1.76)

0.37

1.19 (0.83–1.73)

0.33

Anti-Jo1

0.65 (0.26–1.63)

0.36

0.71 (0.30–1.64)

0.41

Anti-La

0.79 (0.47–1.34)

0.39

0.8 (0.49–1.31)

0.38

Anti-RNP

1.18 (0.791.74)

0.41

1.24 (0.86–1.79)

0.24

Anti-Ro

0.81 (0.56–1.18)

0.27

0.79 (0.55–1.14)

0.21

Anti-Scl70

0.49 (0.15–1.59)

0.24

0.45 (0.14–1.44)

0.19

Anti-Smith

1.43 (0.89–2.27)

0.13

1.44 (0.93–2.22)

0.11

ANCA

0.63 (0.32–1.21)

0.17

0.63 (0.34–1.18)

0.15

Anti-ds DNA

1.52 (1.02–2.29)

0.041

1.48 (1.01–2.16)

0.04

ANA

0.86 (0.38–1.97)

0.72

0.74 (0.36–1.53)

0.42

APLA

0.85 (0.53–1.35)

0.48

0.73 (0.49–1.23)

0.29

AMS adjusted mean SLEDAI-2 K, CI confidence interval, ECG electrocardiogram, HR hazard ratio, SDI SLICC/American College of Rheumatology Damage Index, SLE systemic lupus erythematosus, SLEDAI-2 K SLE Disease Activity Index 2000

Multivariate analysis

ECG-4

The multivariate Cox regression showed that older age, SLE disease activity (AMS 2 years prior to ECG), and SDI are associated with ECG-4. Older patients were more likely to have ECG-4, with a 4% increase in hazard ratio (HR) for every 1-year increase in age (HR = 1.05; 95% confidence interval (CI): 1.01–1.07; p = 0.002). Patients with active SLE (AMS 2 years prior to ECG visit) and patients with more damage (SDI) were more likely to have ECG-4 (HR = 1.08; 95% CI: 1.02–1.16; p = 0.009 and HR = 1.29; 95% CI: 1.1–1.53; p = 0.002, respectively).

Statin treatment for hyperlipidemia was protective against ECG-4 (HR = 0.43; 95% CI: 0.21–0.89; p = 0.02). There was a trend for immunosuppressive therapy to be associated with ECG-4 (p = 0.05). This trend of association can be explained by the use of immunosuppressive therapy in the context of active lupus disease, especially that ECG-4 was also associated with AMS.

ECG-5

The results of the multivariate analysis for ECG-5 were similar to ECG-4, and showed an association with older age (HR = 1.04; 95% CI: 1.007–1.06; p = 0.01), SLE disease activity (AMS 2 years prior to ECG; HR = 1.07 95% CI: 1.002–1.14; p = 0.04), and SDI (HR = 1.28; 95% CI: 1.08–1.51; p = 0.004) (Table 3).
Table 3

Multivariate Cox regression analysis for ECG-4 and ECG-5

 

ECG-4

ECG-5

Variables

HR (95% CI)

p

HR (95% CI)

p

Age at each visit

1.05 (1.01–1.07)

0.002

1.04 (1.007–1.06)

0.01

AMS (2 years prior to ECG)

1.08 (1.02–1.16)

0.009

1.07 (1.002–1.14)

0.04

SDI

1.29 (1.10–1.53)

0.002

1.28 (1.08–1.51)

0.004

Hyperlipidemia on statins ever before ECG

0.44 (0.21–0.89)

0.02

0.44 (0.22–0.87)

0.02

Hypertension

0.66 (0.34–1.26)

0.21

0.75 (0.4–1.39)

0.36

Ever smoked before ECG

1.13 (0.59–2.16)

0.71

1.09 (0.58–2.06)

0.77

Immunosuppressive treatment at each visit

1.88 (1.01–3.51)

0.05

1.67 (0.93–3.04)

0.09

Antimalarial treatment at each visit

1.76 (0.87–3.58)

0.12

1.81 (0.92–3.56)

0.12

Akaike information criterion (AIC) = 334.6

AMS adjusted mean SLEDAI-2 K, CI confidence interval, ECG electrocardiogram, HR hazard ratio, SDI SLICC/American College of Rheumatology Damage Index, SLE systemic lupus erythematosus, SLEDAI-2 K SLE Disease Activity Index 2000

Discussion

It is well established that SLE patients have increased mortality secondary to cardiovascular events even in the absence of traditional risk factors for CVD [15]. In this study of SLE patients, the prevalence of the ECG-4, which have been shown by Chou et al. to be predictive of CVD [14], is 21.4% and the prevalence of ECG-5 is 24.2%. The prevalence of ECG-CVD among SLE patients is greater than the general population (prevalence 3.6–17%) as shown in Table 4. Chou et al. showed that ECG-4 predicts subsequent CVD events [16] and that pathological Q-wave was also a predictor of future CVD [14]. In this study, ECG-CVD (ECG-4 and ECG-5) was more common in patients aged 50.14 ± 14.1 years compared to the group without ECG-CVD (age 44.8 ± 12.9 years); however, this is still younger than the general population.
Table 4

Prevalence of ECG-CVD in the general population

Study

References

Sample size

Mean age (range) in years

ECG-CVD elements in different studies

Prevalence (%)

Chicago Heart Association detection project

Liao et al., 1988 [34]

17,633

51 (40–64)

• ST-segment depression

• T-wave inversion

• LVH

• RBBB/LBBB

• Complete or second AV block

11.1% (female 12.5%, male 9.6%)

Charleston Heart Study

Sutherland et al., 1993 [35]

933

48 (35–74)

• ST-segment depression

• T-wave changes

• LBBB or RBBB

• LAD

• LVH

9%

Fine Study

Menotti and Seccareccia, 1997 [16]

1785

Not reported (65–84)

• Q-QS abnormalities

• ST-T abnormalities

• High R. waves

• Major arrhythmias and blocks

8%

Belgian Inter-University Research

De Becquer et al., 1998 [27]

9954

48 (25–74)

• ST-segment depression

• T-wave inversion

• LBBB or RBBB

• Atrial fibrillation or flutter

3.6%

Copenhagen ECG Study

Rasmussen et al., 2014 [36]

285,194

65

• ST-segment depression

Female 7%

Male 8%

The definition of ECG-CVD varied among the included studies in Table 4

ECG-CVD electrocardiogram cardiovascular disease abnormalities, LAD left axis deviation, LBBB left bundle branch block, LVH left ventricular hypertrophy, RBBB right bundle branch block

In our analysis, we found an association between ECG-CVD (ECG-4 and ECG-5) and lupus disease activity (AMS 2 years prior to ECG) and damage (SDI). Some studies have found an association of azathioprine with atherosclerosis [17, 18]. Although there was a trend in our study for an association with immunosuppressive drugs (azathioprine, mycophenolate mofetil, cyclophosphamide, cyclosporine, and methotrexate), this was not statistically significant. Cumulative glucocorticoid therapy has been postulated as a potential risk factor for atherosclerosis in patients with SLE [2, 19, 20], but not all studies have confirmed this association [21]. In this study, cumulative glucocorticoid therapy and antimalarial drugs were significantly associated with ECG-4 and ECG-5 in the univariate analysis, but did not remain in the multivariate analysis. Statin therapy ever for hyperlipidemia was protective against ECG-CVD in the multivariate analysis.

While some previous studies showed an association between antiphospholipid antibodies and clinical CVD and/or events [20, 22], other studies did not [17, 21, 23]. In the present study, antiphospholipid antibodies were not associated with ECG-4 or ECG-5. More recently, Andrade et al. showed that patients with antiphospholipid syndrome do not develop premature atherosclerosis [24].

Smoking, hypertension, and DM, all recognized as traditional risk factors for CVD in SLE patients [2, 23], were not significantly associated with ECG-CVD this study. Several factors could explain the lack of association with traditional risk factors for CVD in our study. First, smoking ever was reported in 29% of each of the non-CVD and ECG-4 and -5 groups, and other studies have demonstrated the importance of studying the dose-effect (pack-years) of smoking [25]. Second, in CAD, the ECG is the reflection of damage to the myocardium that usually occurs at the end of the process of the development of CAD and its clinical implications. Third, with respect to hypertension, not only is LVH a reflection of long-term inadequate control of blood pressure, but ECG has a poor sensitivity for LVH (slightly lower in females than in males). Fourth, the number of patients with DM was small (only four patients had DM in ECG-4 and -5).

In the current study, the most common element of ECG-4 was ST-segment abnormalities and/or T-wave abnormalities (70%), followed by LVH in 32%, LAD or LAFB in 20%, and LBBB or RBBB in 11%. In ECG-5, Q-wave was found in 18% of the patients. The pooled adjusted HR (for CVD) of ST-segment abnormalities in resting ECG in the normal healthy population from several studies was found to be 1.9 [26–30]. De Bacquer et al. showed that ST‐depression is predictive of CVD [31]. In a recent systematic review, both LVH LAD on resting ECG were associated with a similar increased risk for subsequent CVD events, with a pooled adjusted HR of 1.6 (95% CI, 1.4 to 1.8) [8, 16, 29–32]. LBBB was found in 3% of ECG-CVD, and it has been previously reported that, in the presence of LBBB on resting ECG, there is an increased incidence of ischemic heart disease events and/or death due to cardiovascular disease compared to control subjects [8, 33]. Interestingly, pathological Q-waves were noted in 11% of the patients with ECG-5 without a previous history of ischemic heart disease.

A limitation of this study is the lack of a control group to better evaluate the prevalence of CVD-ECG-4 abnormalities in patients without SLE. In order to evaluate the prevalence of CVD-ECG-4 abnormalities, a baseline ECG should have been done and this is also a limitation of this study. In addition, the low level of correlation among variables in the multivariate analyses is a limitation of this study; although we avoided using variables with moderate to high correlation in the multivariate analyses, some variables were inter-related to each other at a low level, e.g., older age and hyperlipidemia (correlation coefficient = 0.30), and age and dsDNA antibodies (correlation coefficient = –0.22).

Conclusions

SLE is an independent risk factor for cardiovascular disease [17] and therefore early identification of those SLE patients at increased risk for premature cardiovascular disease is crucial to the development and implementation of effective prevention strategies in this population. The high prevalence of ECG-4 and ECG-5 in this study of SLE patients without documented cardiovascular disease suggests that baseline (and possibly follow-up sequential) ECG may be a useful non-invasive SLE screening tool for evaluation and identification of SLE patients at increased risk for cardiovascular events with relatively minimal cost burden. Prospective follow-up studies of SLE patients with ECG-4 and ECG-5 will be helpful to determine the validity of implementation of targeted cardiovascular prevention strategies in patients with ECG-CVD.

Abbreviations

ACR: 

American College of Rheumatology

AIC: 

Akaike information criterion

AMS: 

Adjusted mean SLEDAI-2 K

aPLA: 

Antiphospholipid antibodies

CAD: 

Coronary artery disease

CI: 

Confidence interval

CVD: 

Cardiovascular disease

DM: 

Diabetes mellitus

ECG: 

Electrocardiogram

ECG-CVD: 

Electrocardiogram cardiovascular disease abnormalities

HR: 

Hazard ratio

LAD: 

Left axis deviation

LAFB: 

Left anterior fascicular block

LBBB: 

Left bundle branch block

LVH: 

Left ventricular hypertrophy

MI: 

Myocardial infarction

RBBB: 

Right bundle branch block

SDI: 

SLICC/American College of Rheumatology Damage Index

SLE: 

Systemic lupus erythematosus

SLEDAI-2 K: 

SLE Disease Activity Index 2000

Declarations

Acknowledgements

Not applicable.

Funding

No funding was received for this study.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

Study conception and design: HAR, PJH, DDG, JS, MBU, and ZT. Analysis and interpretation of the data: HAR, PJH, DDG, JS, AS, MBU, and ZT. Preparation of the manuscript: HAR, PJH, DDG, JS, AS, MBU, and ZT. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Research ethics board approval was obtained from the University Health Network, and consent was obtained from all study subjects.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Lupus Clinic, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, EW, 1-412, 399 Bathurst Street, Toronto, Ontario, M5T 2S8, Canada
(2)
Women’s College Research Institute, Women’s College Hospital, University of Toronto, Toronto, Ontario, Canada
(3)
Toronto Western Research Institute, University of Toronto, Toronto, Ontario, Canada

References

  1. Gladman DD, Urowitz MB. Morbidity in systemic lupus erythematosus. J Rheumatol Suppl. 1987;14 Suppl 13:223–6.PubMedGoogle Scholar
  2. Urowitz MB, Ibanez D, Gladman DD. Atherosclerotic vascular events in a single large lupus cohort: prevalence and risk factors. J Rheumatol. 2007;34(1):70–5.PubMedGoogle Scholar
  3. Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus. Results from a single center. II. Predictor variables for mortality. J Rheumatol. 1995;22(7):1265–70.PubMedGoogle Scholar
  4. Petri M, Perez-Gutthann S, Spence D, Hochberg MC. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med. 1992;93(5):513–9.View ArticlePubMedGoogle Scholar
  5. Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger Jr TA, Jansen-McWilliams L, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol. 1997;145(5):408–15.View ArticlePubMedGoogle Scholar
  6. Salmon JE, Roman MJ. Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Am J Med. 2008;121(10 Suppl 1):S3–8.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Lori Mosca EJB. Effectiveness-based guidelines for the prevention of cardiovascular disease in women. Circulation. 2011;123:1243–62.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Chou R, Arora B, Dana T, Fu R, Walker M, Humphrey L. Screening asymptomatic adults with resting or exercise electrocardiography: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2011;155(6):375–85.View ArticlePubMedGoogle Scholar
  9. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.View ArticlePubMedGoogle Scholar
  10. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288–91.PubMedGoogle Scholar
  11. Gladman DD, Urowitz MB. The SLICC/ACR damage index: progress report and experience in the field. Lupus. 1999;8(8):632–7.View ArticlePubMedGoogle Scholar
  12. Touma Z, Gladman DD, Tulloch-Reid D, Toloza SM, Ibanez D, Fortin PR, et al. Burden of autoantibodies and association with disease activity and damage in systemic lupus erythematosus. Clin Exp Rheumatol. 2010;28(4):525–31.PubMedGoogle Scholar
  13. Blackburn H. Classification of the electrocardiogram for population studies: Minnesota Code. J Electrocardiol. 1969;2(3):305–10.View ArticlePubMedGoogle Scholar
  14. Ibanez D, Gladman DD, Urowitz MB. Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2 K is a predictor of outcome in SLE. J Rheumatol. 2005;32(5):824–7.PubMedGoogle Scholar
  15. Roman MJ, Crow MK, Lockshin MD, Devereux RB, Paget SA, Sammaritano L, et al. Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2007;56(10):3412–9.View ArticlePubMedGoogle Scholar
  16. Menotti A, Seccareccia F. Electrocardiographic Minnesota code findings predicting short-term mortality in asymptomatic subjects. The Italian RIFLE Pooling Project (Risk Factors and Life Expectancy). G Ital Cardiol. 1997;27(1):40–9.PubMedGoogle Scholar
  17. Doria A, Shoenfeld Y, Wu R, Gambari PF, Puato M, Ghirardello A, et al. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis. 2003;62(11):1071–7.View ArticlePubMedPubMed CentralGoogle Scholar
  18. Toloza SM, Uribe AG, McGwin Jr G, Alarcon GS, Fessler BJ, Bastian HM, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum. 2004;50(12):3947–57.View ArticlePubMedGoogle Scholar
  19. Urowitz MB, Gladman DD. Late mortality in SLE—“the price we pay for control”. J Rheumatol. 1980;7(3):412–6.PubMedGoogle Scholar
  20. Ahmad Y, Shelmerdine J, Bodill H, Lunt M, Pattrick MG, Teh LS, et al. Subclinical atherosclerosis in systemic lupus erythematosus (SLE): the relative contribution of classic risk factors and the lupus phenotype. Rheumatology (Oxford). 2007;46(6):983–8.View ArticleGoogle Scholar
  21. Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003;349(25):2399–406.View ArticlePubMedGoogle Scholar
  22. Svenungsson E, Jensen-Urstad K, Heimburger M, Silveira A, Hamsten A, de Faire U, et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation. 2001;104(16):1887–93.View ArticlePubMedGoogle Scholar
  23. Asanuma Y, Oeser A, Shintani AK, Turner E, Olsen N, Fazio S, et al. Premature coronary artery atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003;349(25):2407–15.View ArticlePubMedGoogle Scholar
  24. Andrade D, Bortolotto L, Bonfa E, Borba E. Primary antiphospholipid syndrome: absence of premature atherosclerosis in patients without traditional coronary artery disease risk factors. Lupus. 2016;25(5):472–8.View ArticlePubMedGoogle Scholar
  25. Gopal DM, Kalogeropoulos AP, Georgiopoulou VV, Smith AL, Bauer DC, Newman AB, et al. Cigarette smoking exposure and heart failure risk in older adults: the Health, Aging, and Body Composition Study. Am Heart J. 2012;164(2):236–42.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Cuddy TE, Tate RB. Sudden unexpected cardiac death as a function of time since the detection of electrocardiographic and clinical risk factors in apparently healthy men: the Manitoba Follow-Up Study, 1948 to 2004. Can J Cardiol. 2006;22(3):205–11.View ArticlePubMedPubMed CentralGoogle Scholar
  27. De Bacquer D, De Backer G, Kornitzer M, Blackburn H. Prognostic value of ECG findings for total, cardiovascular disease, and coronary heart disease death in men and women. Heart. 1998;80(6):570–7.View ArticlePubMedPubMed CentralGoogle Scholar
  28. Greenland P, Xie X, Liu K, Colangelo L, Liao Y, Daviglus ML, et al. Impact of minor electrocardiographic ST-segment and/or T-wave abnormalities on cardiovascular mortality during long-term follow-up. Am J Cardiol. 2003;91(9):1068–74.View ArticlePubMedGoogle Scholar
  29. Larsen CT, Dahlin J, Blackburn H, Scharling H, Appleyard M, Sigurd B, et al. Prevalence and prognosis of electrocardiographic left ventricular hypertrophy, ST segment depression and negative T-wave; the Copenhagen City Heart Study. Eur Heart J. 2002;23(4):315–24.View ArticlePubMedGoogle Scholar
  30. Machado DB, Crow RS, Boland LL, Hannan PJ, Taylor Jr HA, Folsom AR. Electrocardiographic findings and incident coronary heart disease among participants in the Atherosclerosis Risk in Communities (ARIC) study. Am J Cardiol. 2006;97(8):1176–81.View ArticlePubMedGoogle Scholar
  31. De Bacquer D, De Backer G, Kornitzer M, Myny K, Doyen Z, Blackburn H. Prognostic value of ischemic electrocardiographic findings for cardiovascular mortality in men and women. J Am Coll Cardiol. 1998;32(3):680–5.View ArticlePubMedGoogle Scholar
  32. Brown DW, Giles WH, Croft JB. Left ventricular hypertrophy as a predictor of coronary heart disease mortality and the effect of hypertension. Am Heart J. 2000;140(6):848–56.View ArticlePubMedGoogle Scholar
  33. Pizova NV. Cognitive impairment in systemic lupus erythematosus. Zhurnal Nevrologii i Psihiatrii imeni SS Korsakova. 2013;113(12):113–6.Google Scholar
  34. Liao YL, Liu KA, Dyer A, Schoenberger JA, Shekelle RB, Colette P, et al. Major and minor electrocardiographic abnormalities and risk of death from coronary heart disease, cardiovascular diseases and all causes in men and women. J Am Coll Cardiol. 1988;12(6):1494–500.View ArticlePubMedGoogle Scholar
  35. Sutherland SE, Gazes PC, Keil JE, Gilbert GE, Knapp RG. Electrocardiographic abnormalities and 30-year mortality among white and black men of the Charleston Heart Study. Circulation. 1993;88(6):2685–92.View ArticlePubMedGoogle Scholar
  36. Rasmussen PV, Nielsen JB, Pietersen A, Graff C, Lind B, Struijk JJ, et al. Electrocardiographic precordial ST-segment deviations and the risk of cardiovascular death: results from the Copenhagen ECG Study. J Am Heart Assoc. 2014;3(3):e000549.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us